[Form 4] CME Group Inc. Insider Trading Activity

Rhea-AI Filing Summary

Insider transaction overview: On 06/25/2025 director Robert J. Tierney Jr. filed a Form 4 reporting the acquisition of 532 shares of CME Group Inc. (CME) Class A common stock.

Key details

• Transaction type: Code A – acquisition under the CME Group Director Stock Plan.
• Per-share price reported: $273.03.
• Total shares acquired: 532.
• Beneficial ownership after the transaction: 13,700 direct shares.

The filing indicates the shares were granted pursuant to the company’s director compensation plan rather than an open-market purchase. No derivative securities were reported. The director remains classified as an “Officer/Director” insider and the filing was signed on 06/26/2025 by attorney-in-fact Jenelle Chalmers.

While the size of the acquisition is modest relative to CME’s average daily volume, any increase in board-level ownership can be viewed as enhancing alignment between the director and shareholders.

Positive

• Director increased direct share ownership by 532 shares, improving insider–shareholder alignment.
• No insider sales or derivative disposals were reported, avoiding negative signaling.

Negative

• None.

Insights

Financial Analyst

TL;DR: Director adds 532 CME shares via stock plan; modest, mildly positive alignment signal.

The Form 4 shows Robert J. Tierney Jr. increasing his direct holdings by 3.9 % (532/13,168 prior) at a reference price of $273.03. Because the shares were granted under the director stock plan, cash outlay is not implied, but the additional ownership marginally tightens insider-shareholder alignment. No sales or derivative exercises were disclosed, so there is no negative dilution or signaling effect. From a valuation perspective, 532 shares (~$145k at the reported price) is immaterial to CME’s market cap, yet repeated accumulations by directors can build a constructive sentiment baseline.

Corporate Governance Expert

TL;DR: Routine equity award; governance-neutral, slight positive for incentive alignment.

This grant originates from the board’s approved Director Stock Plan, indicating adherence to predetermined compensation policy and Rule 10b5-1 safe-harbor procedures. The absence of discretionary open-market activity limits interpretation of insider conviction. Nonetheless, holding 13,700 shares links roughly $3.7 million of personal wealth (at $273) to company performance, reinforcing long-term stewardship incentives. There are no red flags regarding compliance, timing, or disclosure quality.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tierney Robert J JR

(Last) (First) (Middle)

20 S. WACKER DRIVE

(Street)

CHICAGO IL 60606

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock Class A	06/25/2025		A(1)		532	A	$273.03	13,700	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Granted pursuant to the CME Group Director Stock Plan, as amended and restated.

Remarks:

	By: Jenelle Chalmers For: Robert J. Tierney Jr.	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many CME shares did director Robert J. Tierney Jr. acquire?

He acquired 532 Class A common shares on 06/25/2025.

At what price were the shares reported in the Form 4 filing?

The filing lists a reference price of $273.03 per share.

What is Robert J. Tierney Jr.'s total beneficial ownership after this transaction?

Following the grant, he directly owns 13,700 CME shares.

Was this an open-market purchase or a stock plan grant?

It was an acquisition under the CME Group Director Stock Plan, coded "A".

Did the filing report any derivative securities activity?

No. Table II showed no transactions involving derivatives.